Andreas Krämer

Andreas Krämer

SGC Frankfurt

Krämer

Andreas Krämer

Affiliations

Biography

Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group led by Stefan Knapp at the SGC Frankfurt as a postdoc, where he was funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer. Afterwards he worked at the Frankfurt Cancer Institute (FCI) as a staff scientist where, among other things, he was responsible for developing a comprehensive screening platform for kinases. In the beginning of 2022, Andreas became a principal investigator and is responsible for running the X-ray crystallography facility unit. His current research interests focus primarily on the structural biology of kinases and E3 ligases.

2024

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example.

Sander P, Schwalm MP, Krämer A, Elson L, Rasch A, Masberg B, Selig R, Sievers-Engler A, Lämmerhofer M, Müller S, Knapp S, Albrecht W, Laufer SA

J Med Chem. 2024-12-17 . .doi: 10.1021/acs.jmedchem.4c02552

PMID: 39681301

Oxadiazolone-Based Aromatic Annulations: A Nitrenoid Precursor for Tricyclic Aminoheterocycles.

Zhu WF, Franz HM, Krämer A, Duman E, Empel C, Göbel MW, Koenigs RM, Knapp S, Hiesinger K, Proschak E, Hernandez-Olmos V

J Org Chem. 2024-10-23 . .doi: 10.1021/acs.joc.4c01622

PMID: 39438325

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, Havener TM, Sanders MK, Brown JW, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

Molecules. 2024-9-14 . 29(17): .doi: 10.3390/molecules29174158

PMID: 39275006

Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors.

Gerninghaus J, Zhubi R, Krämer A, Karim M, Tran DHN, Joerger AC, Schreiber C, Berger LM, Berger BT, Ehret TAL, Elson L, Lenz C, Saxena K, Müller S, Einav S, Knapp S, Hanke T

J Med Chem. 2024-7-19 . .doi: 10.1021/acs.jmedchem.4c00411

PMID: 39028937

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting.

Greco FA, Krämer A, Wahl L, Elson L, Ehret TAL, Gerninghaus J, Möckel J, Müller S, Hanke T, Knapp S

Eur J Med Chem. 2024-7-14 . 276:116672 .doi: 10.1016/j.ejmech.2024.116672

PMID: 39067440

More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.

Ong HW, Yang X, Smith JL, Dickmander RJ, Brown JW, Havener TM, Taft-Benz S, Howell S, Sanders MK, Capener JL, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

J Med Chem. 2024-7-3 . .doi: 10.1021/acs.jmedchem.4c00962

PMID: 38959455

A C-Degron Structure-Based Approach for the Development of Ligands Targeting the E3 Ligase TRIM7.

Muñoz Sosa CJ, Lenz C, Hamann A, Farges F, Dopfer J, Krämer A, Cherkashyna V, Tarnovskiy A, Moroz YS, Proschak E, Němec V, Müller S, Saxena K, Knapp S

ACS Chem Biol. 2024-6-27 . .doi: 10.1021/acschembio.4c00301

PMID: 38934237

Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.

Rak M, Menge A, Tesch R, Berger LM, Balourdas DI, Shevchenko E, Krämer A, Elson L, Berger BT, Abdi I, Wahl LM, Poso A, Kaiser A, Hanke T, Kronenberger T, Joerger AC, Müller S, Knapp S

J Med Chem. 2024-2-29 . .doi: 10.1021/acs.jmedchem.3c02217

PMID: 38422480